Peptide Library

In clinical trials

Digestive & weight

Cagrilintide

Evidence

Clinical trials

Class

Long-acting amylin analog

/

Cagrilintide

KEY TAKEAWAY

Cagrilintide is a long-acting analog of amylin, a hormone released with insulin after meals. Novo Nordisk is developing it for weight management. Cagrilintide is not FDA-approved as a standalone drug and is being studied in clinical trials.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Long-acting amylin analog

Being studied for

Studied for obesity, alone and with semaglutide

Key fact

Cagrilintide is not FDA-approved as a standalone drug and is being studied in clinical trials.

Route

Weekly subcutaneous injection in trials

Evidence strength

Clinical trials

What it is

What it is

Cagrilintide is a long-acting analog of amylin, a hormone released with insulin after meals. Novo Nordisk is developing it for weight management.

How it works

How it works

It acts on amylin and calcitonin receptors in the brain to increase fullness and slow stomach emptying.

Regulatory status

Regulatory status

Cagrilintide is not FDA-approved as a standalone drug and is being studied in clinical trials.

What it is used for

What it is used for

Studied for obesity, alone and with semaglutide.

Side effects and risks

Side effects and risks

Nausea, vomiting and injection-site reactions were the most common effects in trials.

Citations

Citations

Cagrilintide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo